Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CHOP siRNA is a small interfering RNA (siRNA) designed to target and silence the expression of CCAAT/enhancer-binding protein homologous protein (CHOP), also known as DNA damage-inducible transcript 3 (DDIT3). CHOP is a transcription factor that is strongly induced under conditions of severe or prolonged endoplasmic reticulum (ER) stress and acts as a key mediator of ER stress-induced apoptosis. In preclinical research, CHOP siRNA is utilized to investigate the role of CHOP-mediated apoptotic pathways in various pathological conditions, including type 2 diabetes, insulin resistance, ischemic stroke, acute kidney injury, and myocardial ischemia. Silencing CHOP with siRNA has been shown to reduce apoptosis, attenuate inflammatory signaling, and improve cell survival and metabolic homeostasis in various in vitro and in vivo animal models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CHOP siRNA.